CL2007002293A1 - Compuestos derivados de 4-(5-oxo-pirrolidin-amino)-benzonitrilo, moduladores de los receptores de progesterona; composicion farmaceutica; y uso para tratar endometriosis, fibroma uterino, dismenorrea, menorragia, parto prematuro, esterilidad y para p - Google Patents
Compuestos derivados de 4-(5-oxo-pirrolidin-amino)-benzonitrilo, moduladores de los receptores de progesterona; composicion farmaceutica; y uso para tratar endometriosis, fibroma uterino, dismenorrea, menorragia, parto prematuro, esterilidad y para pInfo
- Publication number
- CL2007002293A1 CL2007002293A1 CL200702293A CL2007002293A CL2007002293A1 CL 2007002293 A1 CL2007002293 A1 CL 2007002293A1 CL 200702293 A CL200702293 A CL 200702293A CL 2007002293 A CL2007002293 A CL 2007002293A CL 2007002293 A1 CL2007002293 A1 CL 2007002293A1
- Authority
- CL
- Chile
- Prior art keywords
- menorragy
- dismenorrea
- pirrolidin
- progesterone
- benzonitrile
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82184106P | 2006-08-09 | 2006-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2007002293A1 true CL2007002293A1 (es) | 2008-02-22 |
Family
ID=39082895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200702293A CL2007002293A1 (es) | 2006-08-09 | 2007-08-07 | Compuestos derivados de 4-(5-oxo-pirrolidin-amino)-benzonitrilo, moduladores de los receptores de progesterona; composicion farmaceutica; y uso para tratar endometriosis, fibroma uterino, dismenorrea, menorragia, parto prematuro, esterilidad y para p |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20100210706A1 (es) |
| EP (1) | EP2049104B1 (es) |
| JP (1) | JP5205379B2 (es) |
| KR (1) | KR20090035695A (es) |
| CN (1) | CN101522190A (es) |
| AR (1) | AR062233A1 (es) |
| AU (1) | AU2007284161A1 (es) |
| BR (1) | BRPI0715355A2 (es) |
| CA (1) | CA2660397A1 (es) |
| CL (1) | CL2007002293A1 (es) |
| EA (1) | EA200970189A1 (es) |
| ES (1) | ES2393632T3 (es) |
| MX (1) | MX2009001442A (es) |
| PE (1) | PE20081313A1 (es) |
| TW (1) | TW200825051A (es) |
| WO (1) | WO2008021796A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2607089T3 (es) | 2010-09-03 | 2017-03-29 | Lg Life Sciences Ltd | Método de producción de un compuesto intermedio para sintetizar un medicamento |
| KR101185583B1 (ko) * | 2011-12-27 | 2012-09-24 | 김영재 | 매듭짓는 작업이 필요 없는 봉합사 및 이를 포함하는 키트 |
| TW201534586A (zh) * | 2013-06-11 | 2015-09-16 | Orion Corp | 新穎ｃｙｐ１７抑制劑／抗雄激素劑 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959482A (en) * | 1988-09-26 | 1990-09-25 | Biofor, Ltd. | Pyrrolidinone compounds and pharamaceutical compositions containing same |
| GB9113031D0 (en) | 1991-06-17 | 1991-08-07 | Smithkline Beecham Plc | Compounds |
| WO2004110978A2 (en) * | 2003-06-10 | 2004-12-23 | Smithkline Beecham Corporation | 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors |
| JP2007500245A (ja) * | 2003-06-10 | 2007-01-11 | スミスクライン ビーチャム コーポレーション | 化合物 |
| ES2523017T3 (es) | 2004-03-03 | 2014-11-20 | Glaxosmithkline Llc | Derivados de anilina como moduladores selectivos de los receptores de andrógenos |
| JP2008515998A (ja) * | 2004-10-13 | 2008-05-15 | スミスクライン ビーチャム コーポレーション | 化合物 |
| EP1871379A4 (en) | 2005-04-15 | 2010-06-02 | Glaxosmithkline Llc | CYANOARYLAMINE |
| EP1888512A2 (en) * | 2005-06-06 | 2008-02-20 | Smithkline Beecham Corporation | Chemical compounds |
| JP2009518313A (ja) * | 2005-11-30 | 2009-05-07 | スミスクライン・ビーチャム・コーポレイション | ピロリジンアニリン |
| EP2094269A1 (en) | 2006-12-19 | 2009-09-02 | Smithkline Beecham Corporation | Pyrrolidinanilines |
-
2007
- 2007-08-07 CN CNA2007800376893A patent/CN101522190A/zh active Pending
- 2007-08-07 EP EP07840712A patent/EP2049104B1/en active Active
- 2007-08-07 US US12/374,393 patent/US20100210706A1/en not_active Abandoned
- 2007-08-07 AU AU2007284161A patent/AU2007284161A1/en not_active Abandoned
- 2007-08-07 US US11/834,709 patent/US7816395B2/en active Active
- 2007-08-07 ES ES07840712T patent/ES2393632T3/es active Active
- 2007-08-07 CA CA002660397A patent/CA2660397A1/en not_active Abandoned
- 2007-08-07 WO PCT/US2007/075304 patent/WO2008021796A2/en active Application Filing
- 2007-08-07 EA EA200970189A patent/EA200970189A1/ru unknown
- 2007-08-07 JP JP2009523938A patent/JP5205379B2/ja active Active
- 2007-08-07 MX MX2009001442A patent/MX2009001442A/es unknown
- 2007-08-07 AR ARP070103474A patent/AR062233A1/es not_active Application Discontinuation
- 2007-08-07 KR KR1020097002458A patent/KR20090035695A/ko not_active Application Discontinuation
- 2007-08-07 CL CL200702293A patent/CL2007002293A1/es unknown
- 2007-08-07 TW TW096128929A patent/TW200825051A/zh unknown
- 2007-08-07 BR BRPI0715355-4A patent/BRPI0715355A2/pt not_active IP Right Cessation
- 2007-08-08 PE PE2007001055A patent/PE20081313A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2049104B1 (en) | 2012-09-19 |
| JP2010500366A (ja) | 2010-01-07 |
| PE20081313A1 (es) | 2008-11-15 |
| MX2009001442A (es) | 2009-02-18 |
| EP2049104A2 (en) | 2009-04-22 |
| US20080039517A1 (en) | 2008-02-14 |
| KR20090035695A (ko) | 2009-04-10 |
| WO2008021796A2 (en) | 2008-02-21 |
| ES2393632T3 (es) | 2012-12-26 |
| EA200970189A1 (ru) | 2009-08-28 |
| JP5205379B2 (ja) | 2013-06-05 |
| AR062233A1 (es) | 2008-10-22 |
| BRPI0715355A2 (pt) | 2013-06-18 |
| EP2049104A4 (en) | 2009-09-09 |
| AU2007284161A1 (en) | 2008-02-21 |
| CN101522190A (zh) | 2009-09-02 |
| CA2660397A1 (en) | 2008-02-21 |
| US20100210706A1 (en) | 2010-08-19 |
| US7816395B2 (en) | 2010-10-19 |
| TW200825051A (en) | 2008-06-16 |
| WO2008021796A3 (en) | 2008-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY30573A1 (es) | N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2 | |
| CL2007002199A1 (es) | Compuestos derivados de sulfonil amida, moduladores del receptor cb2; composicion farmaceutica; y su uso para tratar enfermedades inflamatorias y autoinmune. | |
| DE602007006040D1 (de) | Hemmstoffe des progesteron-rezeptors | |
| BRPI0712516A2 (pt) | compostos, composições farmacêuticas, antagonista receptor de a2b, método para uso terapêutico e/ou tratamento profilático e uso de antagonista receptor de a2b | |
| UY32728A (es) | Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia | |
| UY31806A (es) | Compuestos de tiazole y oxazole de sulfonamida de benceno | |
| BRPI0915928A2 (pt) | composições e métodos de uso para anticorpos terapêuticos | |
| CL2011000570A1 (es) | Compuestos derivados de 3-(4-ciano-fenil)-pirazol-5-carboxamida, moduladores del receptor de progesterona; composicion farmaceutica; y su uso para el tratamiento de endometriosis, fibromiomas uterinos, dismenorrea primaria o secundaria, entre otras. | |
| CL2007003832A1 (es) | Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades. | |
| ECSP077233A (es) | Moduladores del receptor de progesterona que comprenden los derivados del pirrol-oxindol y los usos de los mismos | |
| CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
| SV2010003718A (es) | Inhibidores de bace | |
| CL2011000087A1 (es) | Compuestos derivados de heteroarilo sustituido, inhibidores de los receptores dgat1; composicion farmaceutica; y su uso para tratar la diabetes tipo ll y obesidad. | |
| CL2007002971A1 (es) | Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras. | |
| BRPI0917017B8 (pt) | inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos | |
| CL2012001072A1 (es) | Compuestos derivados de feniletinilo, moduladores alostericos positivos del receptor de glutamato (mglur5); procedimiento de preparacion; composicion farmaceutica; y uso para tratar esquizofrenia o enfermedades cognitivas. | |
| UY30572A1 (es) | N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 | |
| UY30610A1 (es) | Moduladores de mglur5 | |
| GT200700064A (es) | Agonistas de ep2 | |
| DOP2011000272A (es) | Derivados de pirazolo usados como antagonistas receptores de ccr4 | |
| ECSP088884A (es) | Compuestos heterociclicos fusionados y su uso como moduladores de mglur5 | |
| CL2007002970A1 (es) | Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras. | |
| CL2009001298A1 (es) | Compuestos derivados de n-ciclohexil-2-fenoxinicotinamida; composición farmcéutica que los comprende; combinación farmacéutica que los comprende; y su uso para tratar una enfermedad mediada por la pde4. | |
| BRPI0916622A2 (pt) | derivados de piperazina usados como moduladores de canal de cálcio cav2,2 | |
| EA201101118A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина |